The HIV shot that could change medicine is facing its biggest test: Getting to patients

Fonte: Business Insider

Trials of lenacapavir, a drug developed by Gilead Sciences, show the twice-a-year shot is almost 100% effective at preventing HIV infection. Ihsaan Haffejee / AFP via Getty ImagesGilead's lenacapavir shows near 100% efficacy in preventing HIV with twice-yearly shots, reports The Telegraph. Some Latin American countries face barriers to accessing lenacapavir despite running crucial trials.